Anika Therapeutics Stock Probability of Future Stock Price Finishing Under 16.04
| ANIK Stock | USD 16.04 0.58 3.49% |
Anika |
Anika Therapeutics Target Price Odds to finish below 16.04
The tendency of Anika Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move below current price in 90 days |
| 16.04 | 90 days | 16.04 | about 10.45 |
Based on a normal probability distribution, the odds of Anika Therapeutics to move below current price in 90 days from now is about 10.45 (This Anika Therapeutics probability density function shows the probability of Anika Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.59 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Anika Therapeutics will likely underperform. Additionally Anika Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Anika Therapeutics Price Density |
| Price |
Predictive Modules for Anika Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Anika Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Anika Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Anika Therapeutics is not an exception. The market had few large corrections towards the Anika Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Anika Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Anika Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.62 | |
β | Beta against Dow Jones | 1.59 | |
σ | Overall volatility | 3.90 | |
Ir | Information ratio | -0.15 |
Anika Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Anika Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Anika Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Anika Therapeutics generated a negative expected return over the last 90 days | |
| Anika Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 166.66 M. Net Loss for the year was (82.67 M) with profit before overhead, payroll, taxes, and interest of 96.78 M. | |
| Anika Therapeutics currently holds about 87.78 M in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01. | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 2491 shares by Anne Nunes of Anika Therapeutics subject to Rule 16b-3 |
Anika Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Anika Stock often depends not only on the future outlook of the current and potential Anika Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Anika Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 14.7 M | |
| Cash And Short Term Investments | 72.9 M |
Anika Therapeutics Technical Analysis
Anika Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Anika Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Anika Therapeutics. In general, you should focus on analyzing Anika Stock price patterns and their correlations with different microeconomic environments and drivers.
Anika Therapeutics Predictive Forecast Models
Anika Therapeutics' time-series forecasting models is one of many Anika Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Anika Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Anika Therapeutics
Checking the ongoing alerts about Anika Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Anika Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Anika Therapeutics generated a negative expected return over the last 90 days | |
| Anika Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 166.66 M. Net Loss for the year was (82.67 M) with profit before overhead, payroll, taxes, and interest of 96.78 M. | |
| Anika Therapeutics currently holds about 87.78 M in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01. | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 2491 shares by Anne Nunes of Anika Therapeutics subject to Rule 16b-3 |
Check out Anika Therapeutics Backtesting, Anika Therapeutics Valuation, Anika Therapeutics Correlation, Anika Therapeutics Hype Analysis, Anika Therapeutics Volatility, Anika Therapeutics History as well as Anika Therapeutics Performance. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.64) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.